title: Hepatic xanthoma associated with pasireotide administration: a first case report.
abstract: Hepatic xanthoma is an extremely rare lesion worldwide. We herein present a case of hepatic xanthoma that developed in a 27-year-old Taiwanese man who had participated in a clinical trial of pasireotide. This is, to the best of our knowledge, the first case of pasireotide-induced hepatic xanthoma. Following discontinuation of the drug, the tumor continued to decrease in size (98.2% decrease in tumor volume). We suggest that, in patients receiving pasireotide, the liver should be checked using periodic radiological examinations, even if the patient does not exhibit any risk factors, and that medical or surgical intervention may not be needed.
authors.affiliation: Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taiwan.
authors.forename: Fan-Chun
authors.initials: FC
authors.lastname: Meng
authors.forename: Tai-Kuang
authors.initials: TK
authors.lastname: Chao
authors.forename: Hsin-Hung
authors.initials: HH
authors.lastname: Huang
mesh_terms: D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000150:complications / Q000175:diagnosis*; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014973:Xanthomatosis / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*
chemical_list: D013004:Somatostatin; C517782:pasireotide